{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:57:57Z","timestamp":1771473477292,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.eplepsyres.2016.06.003","type":"journal-article","created":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T13:46:00Z","timestamp":1468071960000},"page":"98-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs"],"prefix":"10.1016","volume":"126","author":[{"given":"Claudia","family":"St\u00f6llberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Finsterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0005","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.pharep.2014.06.007","article-title":"Chronic administration of phenytoin induces efflux transporter overexpression in rats","volume":"66","author":"Alvariza","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0010","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","article-title":"A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4","volume":"48","author":"Andreasen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2006.07.038","article-title":"Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein","volume":"52","author":"Baltes","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0020","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40268-014-0045-9","article-title":"Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C","volume":"14","author":"Chin","year":"2014","journal-title":"Drugs R. D."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0030","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/sj.bjp.0706830","article-title":"The antiepileptic and anticancer agent valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver","volume":"149","author":"Eyal","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","article-title":"Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans","volume":"76","author":"Giessmann","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/11631540-000000000-00000","article-title":"Management of seizures following a stroke: what are the options?","volume":"29","author":"Gilad","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0045","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0050","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2125.2012.04453.x","article-title":"Oral bioavailability of dabigatran etexilate (Pradaxa(\u00ae)) after co-medication with verapamil in healthy subjects","volume":"75","author":"H\u00e4rtter","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0055","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1177\/1060028013504741","article-title":"Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?","volume":"47","author":"Hellwig","year":"2013","journal-title":"Ann. Pharmacother"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0060","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/j.1476-5381.2009.00634.x","article-title":"Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats","volume":"159","author":"Jing","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0065","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00126334-200408150-00006","article-title":"Coadministration of lopinavir\/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction","volume":"36","author":"Lim","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0070","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/dmd.113.054866","article-title":"Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition","volume":"42","author":"Mikkaichi","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eplepsyres.2010.12.013","article-title":"Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with (11)C-desmethylloperamide","volume":"94","author":"Moerman","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0080","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.0013-9580.2003.06203.x","article-title":"Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate","volume":"44","author":"Nallani","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(24)15285-3","article-title":"In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent","volume":"27","author":"Nicolas","year":"1999","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0090","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1248\/bpb.32.813","article-title":"Induction of drug-metabolizing enzymes by phenobarbital in layered co-culture of a human liver cell line and endothelial cells","volume":"32","author":"Ohno","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0100","first-page":"A6568","article-title":"Pulmonary embolism due to interaction between rivaroxaban and carbamazepine","volume":"157","author":"Risselada","year":"2013","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0105","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4081\/cp.2015.788","article-title":"Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation","volume":"5","author":"Serra","year":"2015","journal-title":"Clin. Pract."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.hrtlng.2014.03.004","article-title":"Prolonged anticoagulant activity of rivaroxaban in a polymorbid elderly female with non-convulsive epileptic state","volume":"43","author":"St\u00f6llberger","year":"2014","journal-title":"Heart Lung"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0115","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/sj.leu.2403390","article-title":"Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1","volume":"18","author":"Tang","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.110.036442","article-title":"Tissue distribution and elimination of [14C]apixaban in rats","volume":"39","author":"Wang","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1528-1167.2006.00414.x","article-title":"Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy","volume":"47","author":"Wang-Tilz","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2016.06.003_bib0135","doi-asserted-by":"crossref","DOI":"10.1002\/phar.1698","article-title":"Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin","author":"Wiggins","year":"2016","journal-title":"Pharmacotherapy"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116300894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121116300894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:35:36Z","timestamp":1760276136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121116300894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":27,"alternative-id":["S0920121116300894"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.06.003","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}